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Growth hormone prevents steroid.induced growth depression in health
and uremia. Treatment with supraphysiological doses of corticosteroids
results in protein wasting and impairment of growth, whereas exoge-
nous growth hormone (GH) causes anabolism and improvement of
growth. We wanted to know whether the growth depressing effects of
methylprednisolone (MP) are more expressed in an organism which is
chronically diseased and whether these effects can be counterbalanced
by concomitant treatment with recombinant human growth hormone
(rhGH). MP in doses from 1 to 9 mg/kg/day caused a dose dependent
reduction of length gain, weight gain and weight gain/food intake ratio
in 140 g healthy female Sprague-Dawley rats. Food intake was not
affected by MP. This points to a change in food metabolism as a
mechanism for growth impairment. In addition, treatment with MP
inhibited endogenous GH secretion, documented by serum GH concen-
tration profiles over seven hours, decreased IGF-l serum concentration
and disturbed growth cartilage plate architecture. Concomitant treat-
ment with 2.5 to 20 IU/rhGH/kg/day prevented the negative effects of
MP on growth in a dose dependent manner and normallized growth
plate architecture, in uremic rats in which food efficiency and growth
was already reduced, 6 mg MP/kg/day further decreased length gain and
prevented weight gain completely by bringing the weight gain/food
conversion ratio to the nadir. All effects of MP including reduction of
muscle mass could be prevented by concomitant treatment with 10 IU
rhGH/kg/day. The effects of MP and rhGH on food efficiency and
growth in uremic animals were numerically nearly identical to those in
pair fed and ad libitum fed controls, but this may be more relevant in the
diseased organism in which basal growth is already suppressed.
Patients receiving corticosteroid treatment for a prolonged
period of time, such as allograft recipients, patients with
steroid-dependent nephrotic syndrome, those with autoimmune
and asthmatic diseases, and many others, manifest side effects
of such treatment. Despite the absence of a marked Cushing
syndrome, protein catabolism [1] and growth impairment [21
may result. Clinical observations suggest that patients with an
underlying chronic disease are more prone to catabolism and
growth failure consequent to corticosteroid treatment than are
otherwise healthy individuals. Therefore, it is of paramount
importance to identify those factors leading to corticosteroid-
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induced protein losses and to develop preventative therapeutic
strategies.
Recombinant human growth hormone (rhGH) is a potent
anabolic agent known to stimulate linear growth in OH deficient
children [31 and in the stunted organism without primary GH
deficiency like the Turner syndrome [41 and chronic renal
failure (CRF) [5—7]. Since rhGH is now available in virtually
unlimited amounts, it has been possible to demonstrate that
rhGH improves nitrogen balance in healthy volunteers [8], in
atheletes [9], in patients receiving parenteral nutrition [101 and
in hypocaloric situations [111. The purpose of the present study
was to determine if the growth depressing effects of methyl-
prednisolone (MP) can be counterbalanced by concomitant
administration of rhGH and if so, whether such an effect is dose
dependent. Furthermore, we addressed the issue of whether a
chronic disease would enhance the growth depressing effects of
corticosteroids, thereby minimizing the growth promoting ef-
fects of rhGH.
Chronic renal failure (CRF) was selected as an example of a
chronic disease. Children with CRF are catabolic and grow
subnormally [12]. Successful renal transplantation does not
normalize growth in a great proportion of patients. The reason
is not fully understood [13]; reduced renal function and corti-
costeroid treatment are two important factors influencing
growth negatively. To mimick the transplant situation and to
evaluate our hypothesis, an animal model was established to
determine the effects of concomitant MP and rhGH treatment.
Methods
Female Sprague-Dawley rats (Ivanovas Co., Kisslegg/Allgau,
Germany), weighing 100 g, were used for the experiment. One
week prior to the study, the animals were kept in single cages at
constant room temperature (24°C) and humidity (70%) on a 12
hours on/12 hours off light cycle. The diet contained: 13800
kilkg; 0.95% calcium; 0.8% phosphorus; 500 lU/kg vitamin D3;
and 18% protein (wt/wt). The animals were subjected to a
two-stage subtotal nephrectomy (NX) as described previously
[5, 141. One week after total nephrectomy of the left kidney, the
contralateral kidney was removed and uremia resulted when the
animals had a mean body weight of 136g. Control animals (CO)
were sham operated (renal decapsulation). Uremic animals and
controls had free access to food (Altromin C 1000 diet, Altromin
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Co., Lage, Lippe, Germany) and deionized water, In addition,
the control group was pair-fed as previously described [14].
Dose response experiments
For dose response experiments, 125 to 150 g healthy female
Sprague-Dawley animals were used. All animals were allowed
free access to food and water. (a) For determining the maximal
dose of rhGH, groups of six animals each were injected with 0,
2.5, 5.0, 10.0, and 20.0 lU/kg rhGH daily during a period of
seven days. (b) For determining the maximal growth depressing
effect of MP, six animals per group were injected s.c. with 1, 3,
6, and 12 mg/kg/day during a period of seven days. In addition,
submaximal doses of(c) MP (2 mg/kg/day) and of(d) rhGH (2.5
lU/kg/day) were combined with increasing doses of rhGH (0 to
10.0 lU/day) or with increasing doses of MP (0 to 12mg/kg/day).
Experiments a through d were performed at different times.
Experimental protocol for concomitant treatment with MP
and rhGH
The animals were randomized into three groups: Group A
received solvent twice daily s.c.; Group B received MP 6mg/kg
daily s.c.; Group C received MP 6 mg/kg daily s.c. and rhGH 5
lU/kg twice daily s.c. All groups (A, B, C) were additionally
divided into three subgroups of five animals each: uremic
animals (NX), sham-operated pair-fed control animals (PF-CO)
and sham-operated ad libitum-fed control animals (ad lib-CO).
The duration of the experiment was 14 days.
Measurements
All measurements of body weight were performed in non-
fasted animals in the afternoon. Nose-tail tip distances were
measured in ether anaesthesia and under conditions of deep
muscle relaxation as described previously [5, 14]. All organs
were weighed before and after desiccation (24 hr; 80°C in the
presence of desiccant). Blood was obtained by aortic puncture
from non-fasted animals at the end of the experiment. Serum
biochemical constituents were measured with a multichannel
Technicon Autoanalyzer (Technicon Instruments, Tarrytown,
New York, USA). Creatinine was determined by a kinetic
method according to Jaffé without deproteinization; the coeffi-
cient of variation within assay was <3%. Blood pressure was
measured by tail plethysmography as described previously [14].
Rat GH was determined using an RIA technique. Antibodies
against rGH and a standard preparation of rGH (RP-2) were
supplied by National Hormone and Pituitary Program (Be-
thesda, Maryland, USA). Rabbit anti-monkey serum was pre-
pared at Kabi (Stockholm, Sweden), and rGH for labelling was
donated by Professor Paul Roos, Uppsala, Sweden. Incubation
was performed at +4°C, initially with samples (in duplicate;
intra assay CV 2 to 8% for GH levels between 0.5 to 8 ng/ml)
or standards together with primary antibodies overnight, fol-
lowed by incubation with labelled rGH for a further 16 hours.
The complexes were precipitated by second antibodies, and
centrifuged. The pellets were counted in a LKB-Wallac Gam-
macounter. Concentrations were calculated. The standard
curve ranged from 0.25 to 16 ng/ml.
For GH pulse analysis (see serum growth hormone profiles
below), a PC version of the PULSAR peak analysis program
[15] was used. The smoothing window was set to 400 minutes,
corresponding to the duration of the profile. A quadratic assay
of SD function was employed which was derived from precision
data of the GH assay given above. G values of 3.0 (Gl), 2.4
(G2), 1.5 (G3), 1.2 (G4) and 1.0 (G5) were employed. In
addition, each profile was inspected visually by estimation of
multiple CVs to check for the plausability of the computer
analysis.
Measurements of IGF-I were done by using an RIA tech-
nique. The antibody was provided by Professor Peter Gluck-
man, New Zealand, and the standard preparation was
recombinant hIGF-I (rhIGF-I; Kabi, Stockholm, Sweden). 25I
lodinated rhIGF-I was used as tracer, Samples were run in
duplicate at two or more dilutions. Incubation was performed at
+4°C overnight in a total volume of 3 ml. Precipitation was
done by the addition of a second antibody in a polyethylene
glycol (PEG) solution, and centrifuged. The pellets were
counted in a LKB-Wallac Gammacounter. Concentrations were
calculated. The standard curve ranged from 0.7 to 11.2 ng/ml.
For histological measurements in the proximal tibia growth
zone, the fluorescent marker calcein was administered to ani-
mals in a single injection (10 mg, s.c.) one week prior to
sacrifice [161. The proximal tibiae were cut in frontal slices and
fixed in 40% (vol/vol) ethanol at +4°C for 24 hours. After
dehydration in a graded series of ethanol at + 20°C, tissue slices
were infiltrated and embedded in methylmethacrylate. After
completion of polymerization at 30°C, 5 m thick sections were
cut in the femoral plane on a Jung microtome No. 1140.
Sections were subsequently mounted on gelatin-coated slides
and stained initially by the von Kossa reaction and subse-
quently with McNeil Tetrachrome [17]. They were used for
morphometric estimations of growth plate height. Ten micro-
meter sections from each tibia were mounted unstained for
measurements of growth rates using incident light fluorescence
microscopy [18].
Serum growth hormone profiles
For growth hormone (GH) profile studies, a separate set of
animals underwent double catheter implantation, according to
the method previously described [19]. At the time of the second
operation for subtotal nephrectomy or sham operation, silastic
cannulas were insertei into the aorta and vena cava through the
ventral tail artery and left external iliac vein, respectively. The
femoral catheter was tunnelled subcutaneously to the tail root
incision, where after wound suture both catheters were exteri-
orized and fixed by means of an acrylic cuff. The GH studies
were performed one week after inducing uremia.
A constant exchange transfusion technique, adapted from
Urbanski, Urbanski and Ojeda [20], was used for the GH
secretion studies: 10 minutes before the start of the study the
catheters were unplugged, flushed with sodium heparin, ex-
tended using polyethylene tubing (PE 50), and connected to the
sampling apparatus through a flexible steel spiral attached to the
plastic cuff. Thus, the animals could move unrestrained within
the cage during the study. Both catheters were connected to a
peristaltic pump (Minipuls 2, Gilson Medical Electronics, Mid-
dleton, Wisconsin, USA), which provided balanced continuous
withdrawal of blood through the arterial catheter and infusion of
a warmed (37°C) blood replacement mixture through the venous
line, Blood was exchanged at a rate of 50 id/mm over a period
of 360 minutes. The withdrawn blood was dispensed at 10
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Table 1. Effects of methyiprednisolone (MP) and recombinant human growth hormone (rhGH) on growth
Daily treatment Cumulative
weight gain
g
Cumulative
length gain
cm
Cumulative
food intake
g
Weight gain
MP rhGH
mg/kg/day I U/kg/day
Food intake
gig
Experiment a 0 0
0
3 0
6 0
9 0
23 1.2
20 1.2 b
18 2.5
14 1.6
14 1.2
2.2 0.12
2.0 0.08 a
2.0 0.12
1.6 0.12
1.8 0.08
100 3.3
96 1.2
99 2.0
91 2.5
92 1.6
0.24 0.004
0.21 0.008 b
0.18 0.020
0.15 0.012
0.14 0.012
Experiment b 0 0
0 2.5
0 5.0
0 10.0
0 20.0
16 2.9
32 2.0 b
36 2.5
35 2.5
41 2.5
1.9 0.12
2.3 0.12
b
2.5 0.04
2.6 0.16
2.6 0.12
91 4.1
97 5.3
98 3.3
96 4.5
106 3.7
0.17 0.029
0.33 0.012
0.36 0.016 b
0.36 0.020
0.39 0.020
Experiment c 0 0
2 0
2 2.5
2 5.0
2 10.0
20 0.41 b
9 2.91 b
21 2.5
23 2.5
31 2.0
b
2.1 0.0411.5 0.08 ' a
1.9 0.12
2.1 0.16
2.4 0.08
b
83 2.0
82 3.7
86 3.7
91 4.1
94 2.0
a
0.24 0.002] a
0.11 0.032 b
0.25 0.020
0.25 0.020
0.33 0.020
b
EXperimentd 0 0
o 2.5
2.5
3 2.5
6 2.5
12 2.5
16 1.6 a
352'5]b21 2.5
14 2.0
19 1.2
14 2.0
b
1.8 0.081 a
2.3±0.O8ja1.9 0,12
1.5 0.08
1.6 0.04
1.4 0.12
b
3.7
115±5.7
113
108 4.5
108 3.7
89 3.3
a
0.15 O.Ol2ja
0.31±0.020]a0.19 0.016
0.14 0.016
0.17 0.012
0.16 0.002
b
Dose Dependency Experiments (n = 6 animals per group, duration of experiments 7 days)
a p < 0.05
b < 0.01
minute fractions and centrifuged approximately every 60 min-
utes. The plasma was stored frozen until assayed for GH and
IGF-I.
The blood replacement mixture was prepared according to
the method of Ellis and Desjardins [21]. Red cells from female
donor rats were washed several times in physiological saline
and resuspended in a charcoal-filtered 2.5% human albumin
solution (Behringwerke AG, Marburg, Germany), adjusted to a
hematocrit of 40%, and containing 0.5 mg glucose/mI, 2 IE
sodium heparin/mI and 100 IU penicillin/mi. The suspension
was stored at +4°C for a maximal period of 24 hours prior to
use. At most, only traces of steroid or GH were detectable in
the substitution fluid,
Statistics
Data are given as X SEM and as median and range. Results
were evaluated using Wilcoxon's test for random samples or
paired differences and the Kruskall Wallis test. Differences at
the 5% level were taken as significant.
Results
Dose response experiments
As shown in Table 1, maximal growth stimulating effects for
length gain and weight gain were obtained by injecting 10 lU/kg
rhGH in two divided doses s.c. daily (Experiment b). The
anabolic effect of rhGH is best seen from the food conversion
ratio, e.g. weight gain per food intake, which is doubled by a
treatment with 5 lU/day (Experiment b). In contrast, MP had a
growth depressing effect on length gain and weight gain. Max-
imal effects were obtained by 6 mg/kg/day, the food conversion
ratio was reduced by one third (Experiment a). Results from
Table 2. Serum growth hormone profile studies in rats treated with
methylprednisolone (MP)
Pair fed control Uremia
Solvent MP Solvent MP
Mean levels 8.9 6.5 9.6 6.3
ng/mI (6.3—27.2) (2.2—8.9) (5.3—30.6) (4.0—10.1)
Total area 3652 1831 5987 2882
mm X ng/ml (2505—11205) (885—2197) (2122—12615) (1650—3832)
Numberof 3 4 4 3
peaks (2—5) (3—6) (1—5) (3—4)
Peak height 10.1 6.4 14.3 5.6
ng/mI (6.2—78.5) (1.0—8.2) (6.6—43.6) (2.9—12.6)
Peak area 409 112 221 151
mm >< ng/ml
Analysis was
(127—2609) (35—161)
performed every 10 minute
(122—1477) (56—224)
s over a period of 7 hours
Experiments c and d demonstrate that the growth stimulating
effects of rhGH can be compensated for by MP and vice versa
in a dose dependent manner
Hormonal studies
Since MP may suppress GH secretion, serum GH concentra-
tions were measured every 10 minutes over a period of seven
hours in five uremic and five pair fed control animals, treated
either with solvent or with 6 mg MP/kg/day (Table 2). There was
no difference between control and uremic animals, but the mean
GH concentration as well as the total area under the curve were
substantially lower in the MP treated animals of both groups.
These differences reached significance (P < 0.05) when MP
animals (control + uremic) were compared with solvent animals
of both groups. The number of GH peaks was not influenced by
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Table 3. Growth in healthy and uremic rats treated with methylprednisolone (MP) and recombinant human growth hormone (rhGH) S.C.
Uremia Pair fed control Ad libitum fed control
Solvent MP MP + GH Solvent MP MP + GH Solvent MP MP + GH
N = 10 animals per group
Wilcoxon test
Cumulative food 163 3 153 14 181 6 163 3 153 4 181 6 193 5 175 5 198 6
intake g
Length gain cm 2.6 0.15c 1.4 0.l5' 2.4 0.15 3.0 0.18 2.! 0.21a 3.2 0.15 3.9 0.11 2.5 0.lla 4.0 0.15
Weight gain g 25.3 2.3C 0.6 l.8a 27.2 2.7 29 2.6 3.4 2.2a 27.7 1.6 43.5 1.4 20.7 J7C 48.5 1.5
x l0- 0.15 0.02c —0.01 0.Ola 0.15 0.02 0.18 0.02 0.02 0.02 0.15 0.01 0.23 0.01 0.12 0.01 0.25 0.01
N = 5 animals per group
Kruskall Wallis test
Initial length mm 352 352 354 361 368 362 358 355 360
(342—356) (345—358) (345—375) (352—376) (352—372) (354—380) (332—365) (351—365) (354—365)
Final length mm 376 360 378 386 378 386 386 372 388
(359—379) (363—360) (368—399) (376—398) (366—384) (376—405) (358—394) (363—390) (378—404)
Initial weight g 136 137 141 151 147 145 146 143 144
(127—144) (136—145) (136—149) (143—153) (139—158) (140—160) (139—153) (136—166) (143—155)
Finalweightg 161 136 164 168 151 175 185 156 195
(140—166) (135—146) (154—180) (156—177) (149—158) (170—187) (167—191) (143—199) (176—211)
Muscle weight dry mg 298d 234b 289 302 256 307 328 296 349
(triceps surae) (254—309) (217—242) (244—332) (249—341) (215—311) (233—323) (276—366) (283—362) (265—391)
Liver weight dry mg 1840 1561" 1770 1906 2319 2392 2060 2167 2194
(1700—1950) (1488—1650) (1468—2085) (1850—2290) (2057—2558) (2094—2864) (1841—2369) (1693—2688) (2163—2740)
Heart weight dry mg 96d 93b 107 137 136 164 153 138 178
(90—102) (88—99) (93—119) (130—161) (134—156) (157—192) (110—178) (124—176) (155—194)
Blood pressure 147C 145 147 110 120 120 120 110 115
mmHg (140—170) (140—165) (130—155) (85—120) (115—130) (115—130) (95—130) (95—130) (95—130)
Difference MP vs. Solvent and MP-GH, P < 0.01b Difference MP vs. Solvent and MP-GH, P 0.05
C Difference Uremia Solvent vs. Control ad lib, P < 0.01
d Difference Uremia Solvent vs. Controls solvent, P 0.05
Difference Uremia Solvent vs. Controls solvent P 0.01
MP treatment, but the peak amplitude as well as the mean peak
area were significantly (P < 0.05) diminished by MP (all MP
animals vs. all solvent animals).
The IGF-I serum concentration was measured in controls fed
ad lib one week after treatment with MP with increasing doses.
There was a significant decrease in the IGF-I concentration:
solvent, 615 38 ng/ml; 3 mg MP/kg/day, 495 38 ng/mI; 6 mg
MP/kg/day, 524 22 ng/ml; 9 mg MP/kg/day, 390 48 ng/ml
(solvent vs. 9 mg MP, P = 0.02).
Concomitant treatment with MP and rhGH
The main experiment (Tables 3 to 5) was done with five
animals per group. To allow unequivocal statistical analysis,
part of the experiment (growth data) was repeated in a second
set with ten animals per group (Table 3, upper part). Maximally
effective doses of MP and rhGH were given concomitantly to
healthy and uremic animals, sham operated control animals
were either pairfed or fed ad libitum. Differences in initial
weight and length between uremic and control animals were due
to the pair feeding protocol [14]. Growth of solvent treated
uremic animals was significantly less than in ad libitum fed
controls, but only insignificantly different from pair fed animals.
In ad libitum fed control animals, MP depressed mean weight
gain by more than 50% and length gain by about one third.
Concomitant treatment with rhGH prevented the suppression
of weight gain and length gain. In uremia, weight gain was
uremic animals were numerically within the range of control
animals.
Neither MP nor rhGH significantly changed the cumulative
food intake of uremic or control animals, although this param-
eter tended to be reduced under the influence of MP and to be
enhanced by rhGH (Table 3). In contrast, MP decreased and
concomitant rhGH normalized the food conversion ratio.
Again, in uremic animals, the effects of MP and of rhGH were
numerically nearly identical when compared to the effects in
controls pairfed or fed ad libitum.
Neither MP nor rhGH had a significant effect on blood
pressure. In comparison to control animals, blood pressure was
significantly higher in uremic animals irrespective of the treat-
ment.
Serum creatinine and urea concentrations were comparable
for uremic animals irrespective of treatment with MP and rhGH
(Table 4), but were significantly higher when compared to
control animals. MP and rhGH had no significant effects on
serum creatinine, urea, electrolyte, glucose or protein concen-
trations in either uremic or control animals. In addition, no
significant changes in urinary calcium and urea excretion were
noted. Creatinine clearance was not influenced by MP, but was
significantly increased by rhGH in the control animals. This
effect was not noted in the uremic animals.
The histomorphometric measurements of the tibial metaphy-
sis (Table 5, Fig. 1) confirm that MP significantly suppresses the
suppressed completely, but all effects of MP on growth of daily growth rate, which can be reversed by concomitant rhGH
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Table 4. Biochemical data in healthy and uremic rats treated with methylprednisolone (MP) and
recombinant human growth hormone (rhGH) sc.
Uremia Pair fed control Ad libitum fed control
Solvent MP MP + OH Solvent MP MP + GH Solvent MP MP + GH
Serum creatinine mg/dl 0.7" 0.7 0.8 0.3 0.3 0.3 0.3 0.3 0.3
(0.6—0.9) (0.7—0.7) (0.5—0.8) (0.2—0.3) (0.2—0.3) (0.3—0.3) (0.2—0.3) (0.3—0.4) (0.3—0.3)
Urea mg/d! 98b 104 102 24 40 31 30 32 27
(75—142) (98—122) (94—142) (20—28) (24—41) (29—38) (25—37) (26—36) (22—29)
K mmol/Iiter 3.9 4.6 4.5 4.0 4.3 4.0 4.1 4.2 4.2
(3.6—4.2) (3.7-4.7) (3.6—4.7) (3.6—4.2) (4.3—4.4) (3.9—4.3) (3.9-4.5) (3.5—4.6) (4.1—4.3)
Ca mmo!/liter 2.6 2.6 2.5 2.6 2.5 2.6 2.5 2.5 2.4
(2.6—2.8) (2.4—2.7) (2.4—2.6) (2.4—2.6) (2.4—2.6) (2.5—2.7) (2.4—2.7) (2.4—2.6) (2.4—2.6)
Pi mmol/liter 2.5 2.5 2.6 1.8 2.3 2.3 2.3 2.3 1.8
(2.1—3.0) (2.1—3.2) (2.0—3.1) (1.7—2.3) (2.0—2.6) (2.0—2.5) (2.2—2.5) (1.8—2.4) (1.6—2.1)
Glucose mg/dI 92 102 98 79 97 96C 93 102 101
(82—99) (82—108) (90—107) (69—103) (89—106) (85—115) (86—105) (96—115) (86—113)
GH (human) ng/ml 0.07 0.11 10.0" 0.08 0.12 15.1" 0.12 0.08 10.9"
(0.05—0.09) (0.05—0.17) (3.3—15.7) (0.04—0.12) (0.10—0.16) (3.3—19.7) (0.02—0.17) (0.06—0.16) (2.8—16.3)
GH (rat) ng/ml 13.0 13.5 2,5c 10.0 8.0 1.0" 9.0 12.0 1,0d
(3.0—19.0) (7.0—19.0) (0.5—11.0) (8.0—19.0) (3.0—14.0) (0.5—4.0) (3.0—22.0) (7.0—14.0) (0.5—2.0)
Urinary Ca mmol/day 0.02 0.02 0.04 0.01 0.01 0.02 0.01 0.01 0.02
(0.02—0.04) (0.01—0.05) (0.03—0.08) (0.01—0.02) (0.01—0.02) (0.01—0.04) (0.01—0.02) (0.01—0.02) (0.01—0.02)
Urea mg/day 428 419 378 465 4948 387 516 430 461
(344—483) (362—453) (269—516) (417—656) (346—632) (341—601) (344—606) (385—469) (362—658)
C1/min/1OOg 348" 326 344 884 841 1l12C 834 820 1230C
(234—434) (233—410) (228—447) (698—1019) (731—1007) (921—1428) (708—1033) (719—1014) (940—1482)
HCO3 mmoll!iter 21.9 l9.5 20.7a — — — 21.8 22.2 23.2
(19.0—23.0) (15.6—20.7) (14.9—23.0) — — — (20.0—25.0) (20.7—24.4) (21.1—24.2)
Blood pH 7.36 7.25" 7.30a — — — 7.35 7.41 7.39
(7.30—7.43) (7.15—7.39) (7.10—7.31) — — — (7.33—7.14) (7.35—7.46) (7.36—7.47)
N = 5 animals per group.
Difference between Uremia and Controls: a P 0.05; b P 0.01
Difference between MP + OH vs. MP and Solvent: "P 0.05; d P 0.01
Table 5. Histomorphometric evaluation of the growth apparatus in the proximal tibia of healthy and uremic rats treated with
methylprednisolone (MP) and recombinant human growth hormone (rhGH) S.C.
Uremia Pair fed control Ad libitum fed control
Solvent MP MP + GH Solvent MP MP + Gil Solvent MP MP + OH
Width of growth zone m 250 f99 263 296 227b 268 252 223b 296
(245—291) (190—246) (210—317) (274—337) (203—238) (253—285) (226—267) (202—261) (274—337)
Rate of growth mlday 101 51" 115 112 79b 99 127 76" 131
(94-1 10) (45—6) (95—123) (101—125) (68—83) (95—115) (116—132) (71—104) (125—155)
N = S per group.
MP vs. solvent and MP + OH: "P0.05; b P0.01
treatment in uremic and control animals. The height of the
growth zone was reduced by MP treatment and significantly
increased by rhGH treatment.
Discussion
The present study demonstrates that the growth depressing
effects corticosteroids can be prevented by concomitant admin-
istration of rhGH in healthy control rats with and without
reduced food intake as well as in rats with CRF. The negative
effects of MP on weight gain and length gain were dose
dependent and could be counterbalanced in a dose dependent
manner by concomitant rhGH. Also disturbance of growth plate
architecture by MP was normalized by rhGH. This is in contrast
to the pessimistic views of Hyams and Carey [221 and Baxter
[23] and provides a rationale for controlled studies in stunted
children treated by corticosteroids for various reasons.
The animals used in this experiment were post-pubertal.
Since epiphyseal closure does not occur during life span of rats,
and growth rate is still high at a body weight of 140 g the rat
model can be used for growth experiments. Female rats seem to
respond better to rhGH than males [51. In uremic animals,
length gain and weight gain did not differ significantly from
pairfed controls but was significantly lower than that observed
in ad lib feditum control animals. This difference is primarily
explained by the diminished food intake and the reduced weight
gain/food intake ratio in uremic animals. The latter is evidence
for catabolism and/or diminished anabolism in uremic animals,
Interestingly, the food efficiency was also impaired in pairfed
controls which had a reduced energy and protein intake.
Already therapeutical doses of MP suppressed length gain
and weight gain of healthy animals (Table 1). Possible mecha-
nisms by which MP influences growth are suppression of
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Fig. 1. Light micrographs of proximal tibia growth plate thick (5xm) sections stained with toluidine blue. A—C. Sham-operated control animals
fed ad libitum receiving either solvent (A), methyiprednisolone (B) or methylprednisolone and growth hormone (C). (Figure I continued on
following page.)
intestinal calcium absorption, protein wasting by catabolism
and/or reduced anabolism, inhibition of GH secretion or direct
effects on chondrocytes and osteoblasts.
Corticosteroids diminish intestinal calcium absorption [24].
In the present study, MP did not have any effect on urinary
calcium and phosphorus secretion, thus confirming the study of
Mitchell, Barr and Pocock [25] who demonstrated that cortico-
steroids have only a minimal effect on calcium absorption in the
rat and that calcium supplements do not improve growth.
The weight gain suppression of MP in rats is in contrast to its
effect in humans, in whom wasting of muscle mass is compen-
sated for by an increasing fat mass. This increase in fat mass is
not seen in rats. The negative effects of MP on linear growth
and body weight was paralleled by a negative effect on muscle
dry weight. Without changing the food intake MP decreased
food conversion ratio in ad libitum fed controls and further
impaired it in uremic and pair fed animals in which food
efficiency was already reduced. Evidently, inhibition of growth
by MP is related to food metabolism and not to food intake. The
decrement in weight gain and weight gain/food intake ratio was
numerically identical in all groups, but in the uremic and the
starving (= pair fed) organism this may be more deleterious,
because basal growth is already suppressed.
Controversy exists concerning suppression of endogenous
GH secretion by corticosteroids. No or even a stimulatory
effect has been reported by various groups [26—28]; however,
Pantelakis et al [29] have observed an almost complete disap-
pearance of GH peaks during a 24 hour study. Similarly, we
have observed the disappearance of GH peaks in MP treated
children following renal transplantation [30]. The discrepancy
may be explained by the view that more physiological doses of
corticosteroids enhance whereas pharmacological doses sup-
press growth hormone secretion [31]. The serum GH profiles
documented in the present study, support the view that GH
secretion is diminished by high doses of MP which may be
partly responsible for the growth depressing effect of MP.
If GH secretion is suppressed by MP one should expect low
circulating IGF-I levels. Cortisol inhibits the production of
IGF-I in liver cells [32] and somatomedin bioactivity was found
to be decreased in humans [33] and in rats [34], but also normal
serum IGF-I levels have been reported in patients with Cushing
syndrome [35] and in subjects receiving corticosteroid therapy
[36]. In the present study, peripheral IGF-I concentration was
significantly lowered only when 9 mg/kg/day MP was given.
This probably indicates a threshold concentration for the effect
of MP. However, interpretation of serum IGF-I values in rats
requires caution because most RIAs—like ours—are not rat
specified and the IGF binding proteins have not been measured
concomitantly. Furthermore, peripheral IGF-I may not reflect
the local production of IGF-I.
In the present study the number of chondrocytes and the
height of the epiphyseal growth plate were reduced by MP. This
is consistent with a previous report for rats [37], in which a
decrease in the size of chondrocytes and a reduced ability of
chondrocytes to replicate and to hypertrophy to osteoblasts
were documented. The cellular effects of corticosteroids appear
to be dependent on the concentration at the target organs
including growth cartilage and bone. In physiological concen-
trations. corticosteroids positively modulate the responsiveness
of cells to anabolic effects of exogenous IGF-I [38] and regulate
the basal activity and hormone responsiveness of osteoblasts
[39], They also up-regulate receptors for various hormones, like
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Fig. 1. Cont'd. D—F. Uremic animals receiving solvent (D), methylprednisolone (E) or methylprednisolone and growth hormone (F). In control
and uremic animals, height of growth plate is reduced by methylprednisolone (B and E). The reduction in height is attributable to a decrease in
the number of proliferating and mainly hypertrophic chondrocytes within cell columns. Concomitant treatment with growth hormone (C and D)
not only normalized the height of growth plate but increased the number of hypertrophic chondrocytes in comparison with solvent treated animals
(A and D). (x 125: 1).
I ,25(OH)2D3 [40] and PTH [41]. High doses of corticosteroids
decrease bone formation [42] and interfere with skeletal growth
at the sites of growth cartilage [371. Potential mechanisms
which may explain the negative effects of high dose corticoste-
roids on growth, are the inhibition of local production of IGF-I
[43, 441.
rhGH in supraphysiological doses improves growth in short
children with [31 and without GH deficiency [41, and in children
and animals with CRF [5—71. It leads to positive nitrogen
balance in stunted children [45], healthy adult volunteers [8]
and in hypocaloric situations [11]. For epiphyseal growth, GH
acts directly, via peripheral IGF-I and by local production of
IGF-I on the proliferation and differentiation of chondrocytes
[46]. Taking all studies on the effects of MP and rhGH together
one might speculate that the local production of IGF-I and the
modulation of cell response to IGF-I are the final common
pathway affected by both corticosteroids and GH.
In the present study rhGH counterbalanced the growth
depressing effects of MP in a dose dependent manner. In
comparison to humans, higher doses of rhGH are needed in rats
to see significant effects of rhGH on growth [5]; marked effects
were noted with 2.5 lU/kg/day (Table I) which is more than ten
times the dose used in uremic children. The increments in
length gain, weight gain and weight gain/food intake ratio were
numerically nearly identical in both control groups and in
uremic rats. It is tempting to try to compensate the negative
effects of corticosteroids on growth by rhGH in clinical studies.
Recently, Horber and Haymond demonstrated that N wasting
by prednisone can be prevented by concomitant rhGH in
humans [81. We and others could improve growth and muscle
mass by rhGH in some, but not all children with renal allografts
treated by corticosteoids [47—49]. Remarkably, our patients
who did not grow despite normal glomerular filtration rate
(GFR) responded well to rhGH. This points to steoids as a
major determinant for growth suppression in these children.
Several potential side effects must be considered in such
studies. Carbohydrate intolerance and insulin resistance has
been noted following administration of either substance [50,
511. Glomerular hyperfiltration [52] following rhGH treatment
must be discussed as a reason for deterioration of renal function
in the long run. In this study, C. was not affected by MP but
increased significantly by rhGH in controls. The increase in CC.
was not paralleled by a change in serum creatinine concentra-
tion, which is dependent on renal function and muscle mass and
metabolism. Under rhGH treatment muscle is in an anabolic
state and it is not known whether steady-state conditions for
creatinine have been reached after 14 days. The effect of rhGH
On Ccr was abolished in uremic animals. Although GFR was
measured by an imperfect method in a small number of animals,
the results are in line with our short-term inulin studies in man
which showed that C1 was increased by rhGH only in healthy
controls but not in patients with CRF [53]. The reason for the
different renal effects of rhGH in health and CRF may be
resistance to GH in uremia or absence of glomerular reserve
capacity. Finally, it has to be established whether rhGH coun-
terbalances not only the growth depressing effects of MP but
also the immunosuppression. Clinical studies in allograft recip-
ients [47—49] are not conclusive at this moment.
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